RSSL hires pharmaceutical consultant

Louis McMahon takes a troubleshooting role

Dr Louis McMahon has joined RSSL Pharma as pharmaceutical consultant. He will liaise between RSSL Pharma's scientists and their customers, particularly in a troubleshooting role, helping customers to understand the implication of analytical results and to respond as necessary.

McMahon previously held senior positions at Novartis, Biovail, Wyeth and Pfizer. He is a European registered toxicologist, and was formerly an analytical development manager and forensic lead at Pfizer Newbridge, where he helped establish the company's site analytical development and industrial forensic capabilities.

You may also like

Analysis

RSSL launches new biotech innovation hub

Reading Scientific Services Limited has announced plans to launch its new innovation hub for pharmaceutical clients to have access to collaborate
Analysis

FREE WEBINAR: Best Practices in Environmental Monitoring

The webinar will be hosted on Thursday, 2 July, 3pm-4pm (BST)
Regulatory

Ethypharm and RSSL partnership fast-tracks priority medicine

Ethypharm has collaborated with RSSL to accelerate the manufacture and batch release of fentanyl injection
Analysis

FREE WEBINAR: Investigating sterility test failures

The webinar will be hosted on Thursday 4 June 2pm – 3pm (BST)
Finance

2019 Cleanroom Business Round-up

Key mergers, acquisitions and new businesses of the past 12 months
Analysis

RSSL launches sterility testing service

The global CRO further expands biopharmaceutical services to meet client demand and market growth
Regulatory

Adequately establishing contamination risk in drug products

Recent changes within the United States Pharmacopoeia (USP) and European Pharmacopoeia (EP) put emphasis on risk assessment for the likelihood of contamination as opposed to enforcing mandatory testing in drug products, Alan Cross, technical specialist, metals laboratory at RSSL, explains
Subscribe now